The Goldman Sachs Group Initiates Coverage on Sanofi (NASDAQ:SNY)

by · The Cerbat Gem

Equities researchers at The Goldman Sachs Group started coverage on shares of Sanofi (NASDAQ:SNY – Get Free Report) in a research note issued on Friday, Marketbeat Ratings reports. The brokerage set a “neutral” rating and a $65.00 price target on the stock. The Goldman Sachs Group’s price target would indicate a potential upside of 12.48% from the company’s previous close.

Several other analysts have also issued reports on the company. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Three analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $62.50.

Read Our Latest Research Report on Sanofi

Sanofi Stock Performance

Shares of SNY opened at $57.79 on Friday. The company has a market cap of $146.66 billion, a PE ratio of 23.21, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The stock has a 50-day moving average price of $54.39 and a 200-day moving average price of $52.92. Sanofi has a 12-month low of $45.22 and a 12-month high of $60.12.

Sanofi (NASDAQ:SNY – Get Free Report) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, equities analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Institutional Trading of Sanofi

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Synergy Asset Management LLC bought a new stake in Sanofi in the fourth quarter valued at approximately $25,000. McClarren Financial Advisors Inc. lifted its position in Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares during the last quarter. Lee Danner & Bass Inc. bought a new stake in Sanofi in the fourth quarter valued at approximately $31,000. Bessemer Group Inc. lifted its position in Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company’s stock valued at $32,000 after purchasing an additional 242 shares during the last quarter. Finally, Sunbelt Securities Inc. lifted its position in Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after purchasing an additional 313 shares during the last quarter. Institutional investors own 14.04% of the company’s stock.

Sanofi Company Profile

(Get Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

See Also